3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
33
Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
mCRPC
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Salivary Cancer
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Melanoma
1
Liposarcoma
1
Lethal Congenital Contracture Syndrome 2
1
Fibromatosis, Gingival, 2
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Dementia
1
Colorectal Neoplasms
1
Cognitive Dysfunction
1
Castration-resistant Prostate Cancer Patients with Oligometastases
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
enzalutamide
1
apalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Metastatic Hormone-sensitive Prostate Cancer
×
enzalutamide
×
Clear all
NCT05901649
2026-06-05
ArtemisPRO
Janssen-Cilag Ltd.
Active not recruiting
504 enrolled